

HCSC (BCBSIL, BCBSMT, BCBSNM, BCBSOK, BCBSTX) Medicaid and Medicare Medical Drug Management Code List

*****Please note: This list is constantly evolving as new drugs come to market and are approved by the FDA as well as with any HCPC code changes issued by CMS. Please contact HCSC or EviCore, if the drug you are requesting is not contained on this list, to determine if prior authorization is needed*****

Effective Date: 04/01/2024

Description	Alt Descriptions	HCPCs code	Program	Therapeutic Drug Category	HCSC (BCBS IL, MT, NM, OK, TX)	Drug Comments
Abatacept	Orencia	J0129	Medical Drug Managment	Analgesic and Anesthetic Agents	Y	
AbobotulinumtoxinA	Dysport	J0586	Medical Drug Managment	Neuromusclar Drugs	Y	
Adacanumab-avwa	Aduhelm	J0172	Medical Drug Managment	Misc Psychotherapeutic and Neurological Agents	Y	
ADAMTS13, Recombinant-krhn	Adzynma	C9399	Medical Drug Managment	Congenital thrombotic thrombocytopenic purpura	Y	C9167 will replace C9399 for Adzynma, effective: 04/01/24
ADAMTS13, Recombinant-krhn	Adzynma	C9167	Medical Drug Managment	Congenital thrombotic thrombocytopenic purpura	Y	C9167 will replace C9399 for Adzynma, effective: 04/01/24
ADAMTS13, Recombinant-krhn	Adzynma	J3590	Medical Drug Managment	Congenital thrombotic thrombocytopenic purpura	Y	
Afamelanotide	Scenesse	J7352	Medical Drug Managment	Topical Products	Y	
Aflibercept	Eylea	J0178	Medical Drug Managment	Dermatological/Anorectal /Mouth- Throat/Dental/Ophthalmi c/Otic	Y	
Aflibercept	Eylea HD	J0177	Medical Drug Managment	Dermatological/Anorectal /Mouth- Throat/Dental/Ophthalmi c/Otic	Y	New Permanent HCPC Code: J0177 will replace NOC Codes: C9161 & J3590 for Aflibercept (Eylea HD) effective: 04/01/24

Effective Date: 04/01/2024

Description	Alt Descriptions	HCPCs code	Program	Therapeutic Drug Category	HCSC (BCBS IL, MT, NM, OK, TX)	Drug Comments
Aflibercept	Eylea HD	C9161	Medical Drug Managment	Dermatological/Anorectal /Mouth- Throat/Dental/Ophthalmic/Otic	Y	New Permanent HCPC Code: J0177 will replace NOC Codes: C9161 & J3590 for Aflibercept (Eylea HD) effective: 04/01/24
Aflibercept	Eylea HD	J3590	Medical Drug Managment	Dermatological/Anorectal /Mouth- Throat/Dental/Ophthalmic/Otic	Y	New Permanent HCPC Code: J0177 will replace NOC Codes: C9161 & J3590 for Aflibercept (Eylea HD) effective: 04/01/24
Agalsidase Beta	Fabrazyme	J0180	Medical Drug Managment	Endocrine and Metabolic Drugs	Y	
Alemtuzumab	Lemtrada	J0202	Medical Drug Managment	Psychotherapeutic and Neurological Agents	Y	
Alglucosidase Alfa	Lumizyme	J0221	Medical Drug Managment	Endocrine and Metabolic Drugs	Y	
Alpha1-proteinase inhibitors	Aralast NP, Prolastin-C, Zemaira	J0256	Medical Drug Managment	Respiratory Agents	Y	
Alpha1-proteinase inhibitors	Glassia	J0257	Medical Drug Managment	Respiratory Agents	Y	
Anifrolumab-fnia	Saphnelo	J0491	Medical Drug Managment	Miscellaneous Products	Y	
Apomorphine	Apokyn	J0364	Medical Drug Managment	Neuromusclar Drugs	Y	
Avacincaptad pegol	Izervay	J2801	Medical Drug Managment	Dermatological/Anorectal /Mouth- Throat/Dental/Ophthalmic/Otic	Y	New permanent HCPC Code: J2801 will replace NOC Codes: C9162 & J3490 for Izervay, effective: 04/01/24
Avacincaptad pegol	Izervay	C9162	Medical Drug Managment	Dermatological/Anorectal /Mouth- Throat/Dental/Ophthalmic/Otic	Y	New permanent HCPC Code: J2801 will replace NOC Codes: C9162 & J3490 for Izervay, effective: 04/01/24
Avacincaptad pegol	Izervay	J3490	Medical Drug Managment	Dermatological/Anorectal /Mouth- Throat/Dental/Ophthalmic/Otic	Y	New permanent HCPC Code: J2801 will replace NOC Codes: C9162 & J3490 for Izervay, effective: 04/01/24
Avalglucosidase alfa-ngpt	Nexviazyme	J0219	Medical Drug Managment	Endocrine and Metabolic Drugs	Y	
Belimumab	Benlysta	J0490	Medical Drug Managment	Miscellaneous Products	Y	
Benralizumab	Fasenra	J0517	Medical Drug Managment	Respiratory Agents	Y	
Bezlotoxumab	Zinplava	J0565	Medical Drug Managment	Biologicals	Y	
Bimatoprost Intracameral implant	Durysta	J7351	Medical Drug Managment	Dermatological/Anorectal /Mouth- Throat/Dental/Ophthalmic/Otic	Y	

Effective Date: 04/01/2024

Description	Alt Descriptions	HCPCs code	Program	Therapeutic Drug Category	HCSC (BCBS IL, MT, NM, OK, TX)	Drug Comments
Brexanolone	Zulresso	J1632	Medical Drug Managment	Central Nervous Systems Drugs	Y	
Brolucizumab-dblb	Beovu	J0179	Medical Drug Managment	Dermatological/Anorectal /Mouth-Throat/Dental/Ophthalmic/Otic	Y	
Burosumab-twza	Crysvita	J0584	Medical Drug Managment	Endocrine and Metabolic Drugs	Y	
C1 Esterase Inhibitor	Berinert	J0597	Medical Drug Managment	Hematological Agents	Y	
C1 Esterase Inhibitor	Cinryze	J0598	Medical Drug Managment	Hematological Agents	Y	
C1 Esterase Inhibitor	Ruconest	J0596	Medical Drug Managment	Hematological Agents	Y	
Cabotegravir and Rilpivirine	Cabenuva	J0741	Medical Drug Managment	Anti-Infective Agents	Y	
Cabotegravir extended-release injectable suspension	Apertude	J0739	Medical Drug Managment	Anti-Infective Agents	Y	
Canakinumab	Ilaris	J0638	Medical Drug Managment	Analgesics and Anesthetics	Y	
Caplacizumab-yhdp	Cablivi	C9047	Medical Drug Managment	Hematological Agents	Y	
Caplacizumab-yhdp	Cablivi	J3590	Medical Drug Managment	Hematological Agents	Y	
Casimersen	Amondys 45	J1426	Medical Drug Managment	Neuromusclar Drugs	Y	
Cipaglucosidase alfa-atga	Pombiliti	J1203	Medical Drug Managment	Treatment of late-onset Pompe disease	Y	New permanent HCPC Code: J1203 will replace NOC Codes: C9399 & J3590 for Pombiliti, effective: 04/01/24
Cipaglucosidase alfa-atga	Pombiliti	C9399	Medical Drug Managment	Treatment of late-onset Pompe disease	Y	New permanent HCPC Code: J1203 will replace NOC Codes: C9399 & J3590 for Pombiliti, effective: 04/01/24
Cipaglucosidase alfa-atga	Pombiliti	J3590	Medical Drug Managment	Treatment of late-onset Pompe disease	Y	New permanent HCPC Code: J1203 will replace NOC Codes: C9399 & J3590 for Pombiliti, effective: 04/01/24
Collagenase Clostridium Histolyticum	Xiaflex	J0775	Medical Drug Managment	Miscellaneous Products	Y	
Corticotropin	H.P. Acthar	J0800	Medical Drug Managment	Endocrine and Metabolic Drugs	Y	
Crizanlizumab-tmca	Adakveo	J0791	Medical Drug Managment	Hematological Agents	Y	
Darbepoetin Alfa	Aranesp, Aranesp for NON-ESRD	J0881	Medical Drug Managment	Hematological Agents	Y	

Effective Date: 04/01/2024

Description	Alt Descriptions	HCPCs code	Program	Therapeutic Drug Category	HCSC (BCBS IL, MT, NM, OK, TX)	Drug Comments
DaxibotulinumtoxinA-lanm	Daxxify	J0589	Medical Drug Managment	Topical Products	Y	New permanent HCPC Code: J0589 will replace NOC Codes: C9160 & J3590 for Daxxify, effective: 04/01/24
DaxibotulinumtoxinA-lanm	Daxxify	C9160	Medical Drug Managment	Topical Products	Y	New permanent HCPC Code: J0589 will replace NOC Codes: C9160 & J3590 for Daxxify, effective: 04/01/24
DaxibotulinumtoxinA-lanm	Daxxify	J3590	Medical Drug Managment	Topical Products	Y	New permanent HCPC Code: J0589 will replace NOC Codes: C9160 & J3590 for Daxxify, effective: 04/01/24
Delandistrogene Moxeparvovec-rokl	Elevidys	J1413	Medical Drug Managment	Neuromusclar Drugs	Y	
Delandistrogene Moxeparvovec-rokl	Elevidys	C9399	Medical Drug Managment	Neuromusclar Drugs	Y	
Delandistrogene Moxeparvovec-rokl	Elevidys	J3590	Medical Drug Managment	Neuromusclar Drugs	Y	
Denosumab	Prolia	J0897	Medical Drug Managment	Endocrine and Metabolic Drugs	Y	
Ecallantide	Kalbitor	J1290	Medical Drug Managment	Hematological Agents	Y	
Eculizumab	Soliris	J1300	Medical Drug Managment	Hematological Agents	Y	
Edaravone	Radicava	J1301	Medical Drug Managment	Neuromusclar Drugs	Y	
Efgartigimod alfa-fcab	Vyvgart	J9332	Medical Drug Managment	Miscellaneous Products	Y	
Efgartigimod alfa-fcab & Hyaluronidase-qvfc	Vyvgart Hytrulo	J9334	Medical Drug Managment	Miscellaneous Products	Y	
Efgartigimod alfa-fcab & Hyaluronidase-qvfc	Vyvgart Hytrulo	C9399	Medical Drug Managment	Miscellaneous Products	Y	
Efgartigimod alfa-fcab & Hyaluronidase-qvfc	Vyvgart Hytrulo	J3590	Medical Drug Managment	Miscellaneous Products	Y	
Elapegademase-lvlr	Revcovi	C9399	Medical Drug Managment	ADA-SCID	Y	
Elapegademase-lvlr	Revcovi	J3590	Medical Drug Managment	ADA-SCID	Y	
Elosulfase Alfa	Vimizim	J1322	Medical Drug Managment	Endocrine and Metabolic Drugs	Y	
Epoetin Alfa	Epogen, Procrit	J0885	Medical Drug Managment	Hematological Agents	Y	
Epoetin alfa - epbx	Retacrit	Q5106	Medical Drug Managment	Hematological Agents	Y	
Epoprostenol	Epoprostenol, Flolan, Veletri	J1325	Medical Drug Managment	Cardiovascular Agents	Y	
Eptinezumab-jjmr (Vyepti)	Vyepti	J3032	Medical Drug Managment	Analgesics and Anesthetics	Y	

Effective Date: 04/01/2024

Description	Alt Descriptions	HCPCs code	Program	Therapeutic Drug Category	HCSC (BCBS IL, MT, NM, OK, TX)	Drug Comments
Esketamine	Spravato	S0013	Medical Drug Managment	Central Nervous Systems Drugs	Y	
Etelcalcetide Injection	Parsabiv	J0606	Medical Drug Managment	Endocrine and Metabolic Drugs	Y	
Eteplirsen	Exondys 51	J1428	Medical Drug Managment	Neuromusclar Drugs	Y	
Etranacogene Dezaparvovec-drlb	Hemgenix	J1411	Medical Drug Managment	Hematological Agents	Y	
Evinacumab-dgnb	Evkeeza	J1305	Medical Drug Managment	Cardiovascular Agents	Y	
Factor IX (antihemophilic factor, recombinant), glycopegylated	Rebinyon	J7203	Medical Drug Managment	Hematological Agents	Y	
Factor VIII / VON Willebrand Factor Complex, Recombinant	Altuviiiio per factor viiii iu	J7214	Medical Drug Managment	Hematological Agents	Y	
Faricimab-svoa	Vabysmo	J2777	Medical Drug Managment	Dermatological/Anorectal /Mouth-Throat/Dental/Ophthalmic/Otic	Y	
Fecal Microbiota, Live-jsl	Rebyota	J1440	Medical Drug Managment	Gastrointestinal Agents	Y	
Filgrastim	Neupogen	J1442	Medical Drug Managment	Hematological Agents	Y	
Filgrastim-aafi	Nivestym	Q5110	Medical Drug Managment	Hematological Agents	Y	
Filgrastim-ayow	Releuko	Q5125	Medical Drug Managment	Hematological Agents	Y	
Filgrastim-sndz	Zarxio	Q5101	Medical Drug Managment	Hematological Agents	Y	
Fosdenopterin	Nulibry	C9399	Medical Drug Managment	Molybdenum Cofactor Deficiency	Y	
Fosdenopterin	Nulibry	J3490	Medical Drug Managment	Molybdenum Cofactor Deficiency	Y	
Galsulfase	Naglazyme	J1458	Medical Drug Managment	Endocrine and Metabolic Drugs	Y	
Givosiran	Givlaari	J0223	Medical Drug Managment	Hematological Agents	Y	
Golimumab	Simponi Aria	J1602	Medical Drug Managment	Analgesics and Anesthetics	Y	
Golodirsen	Vyondys 53	J1429	Medical Drug Managment	Neuromusclar Drugs	Y	
Histrelin Acetate	Supprelin LA	J9226	Medical Drug Managment	Endocrine and Metabolic Drugs	Y	
Ibalizumab-uryk	Trogarzo	J1746	Medical Drug Managment	Anti-Infective Agents	Y	
Idursulfase	Elaprase	J1743	Medical Drug Managment	Endocrine and Metabolic Drugs	Y	
Imiglucerase	Cerezyme	J1786	Medical Drug Managment	Hematological Agents	Y	

Effective Date: 04/01/2024

Description	Alt Descriptions	HCPCs code	Program	Therapeutic Drug Category	HCSC (BCBS IL, MT, NM, OK, TX)	Drug Comments
Immune Globulin	Bivigam	J1556	Medical Drug Managment	Biologicals	Y	
Immune Globulin	Carimune NF, Gammagard S/D, Panglobulin NF	J1566	Medical Drug Managment	Biologicals	Y	
Immune Globulin	Cuvitru	J1555	Medical Drug Managment	Biologicals	Y	
Immune Globulin	Cuvitru, Cutaquig, Gammagard, Gammaked, Gamunex-C, Hizentra, Xembify	90284	Medical Drug Managment	Biologicals	Y	
Immune Globulin	Flebogamma DIF	J1572	Medical Drug Managment	Biologicals	Y	
Immune Globulin	Gammagard liquid	J1569	Medical Drug Managment	Biologicals	Y	
Immune Globulin	Gammagard, Asceniv, Panzyga, Bivigam, Flebogamma, Gammaked, Gamunex-C, Gammaplex, Octagam, Privigen	90283	Medical Drug Managment	Biologicals	Y	
Immune Globulin	Gammaplex	J1557	Medical Drug Managment	Biologicals	Y	
Immune Globulin	Gamunex-C, Gammaked	J1561	Medical Drug Managment	Biologicals	Y	
Immune Globulin	Hizentra	J1559	Medical Drug Managment	Biologicals	Y	
Immune Globulin	Hyqvia	J1575	Medical Drug Managment	Biologicals	Y	
Immune Globulin	Octagam	J1568	Medical Drug Managment	Biologicals	Y	
Immune Globulin	Panzyga	J1576	Medical Drug Managment	Biologicals	Y	
Immune Globulin	Panzyga, Immune Globulin (not otherwise specified)	J1599	Medical Drug Managment	Biologicals	Y	
Immune Globulin	Privigen	J1459	Medical Drug Managment	Biologicals	Y	
Immune Globulin intravenous, human - sira	Asceniv	J1554	Medical Drug Managment	Biologicals	Y	
Immune Globulin intravenous, human - sira	Asceniv	J1599	Medical Drug Managment	Biologicals	Y	
Immune Globulin Subcutaneous, human - klhw	Xembify	J1558	Medical Drug Managment	Biologicals	Y	
Immune Globulin Subcutaneous	Cutaquig	J1551	Medical Drug Managment	Biologicals	Y	
Inclisiran	Leqvio	J1306	Medical Drug Managment	Cardiovascular Agents	Y	
IncobotulinumtoxinA	Xeomin	J0588	Medical Drug Managment	Neuromusclar Drugs	Y	
Inebilizumab-cdon	Uplizna	J1823	Medical Drug Managment	Miscellaneous Products	Y	

Effective Date: 04/01/2024

Description	Alt Descriptions	HCPCs code	Program	Therapeutic Drug Category	HCSC (BCBS IL, MT, NM, OK, TX)	Drug Comments
Infliximab	Inflectra	Q5103	Medical Drug Managment	Gastrointestinal Agents	Y	
Infliximab	Remicade	J1745	Medical Drug Managment	Gastrointestinal Agents	Y	
Infliximab-abda	Renflexis	Q5104	Medical Drug Managment	Gastrointestinal Agents	Y	
Infliximab-axxq	Avsola	Q5121	Medical Drug Managment	Gastrointestinal Agents	Y	
Injection, romosozumab-aqqg, 1 mg	Evenity	J3111	Medical Drug Managment	Endocrine and Metabolic Drugs	Y	
Interferon Gamma-1 b	Actimmune	J9216	Medical Drug Managment	Antineoplastic Agents and Adjunctive Therapies	Y	
Intra-Articular Hyaluronan Injections	Durolane	J7318	Medical Drug Managment	Neuromusclar Drugs	Y	
Intra-Articular Hyaluronan Injections	Euflexxa	J7323	Medical Drug Managment	Neuromusclar Drugs	Y	
Intra-Articular Hyaluronan Injections	Gel-One	J7326	Medical Drug Managment	Neuromusclar Drugs	Y	
Intra-Articular Hyaluronan Injections	Gelsyn-3	J7328	Medical Drug Managment	Neuromusclar Drugs	Y	
Intra-Articular Hyaluronan Injections	Genvisc 850	J7320	Medical Drug Managment	Neuromusclar Drugs	Y	
Intra-Articular Hyaluronan Injections	Hyalgan, Supartz, Supartz FX, (Visco-3 as of 4/1/21)	J7321	Medical Drug Managment	Neuromusclar Drugs	Y	
Intra-Articular Hyaluronan Injections	Hymovis	J7322	Medical Drug Managment	Neuromusclar Drugs	Y	
Intra-Articular Hyaluronan Injections	Monovisc	J7327	Medical Drug Managment	Neuromusclar Drugs	Y	
Intra-Articular Hyaluronan Injections	Orthovisc	J7324	Medical Drug Managment	Neuromusclar Drugs	Y	
Intra-Articular Hyaluronan Injections	Sodium hyaluronate 1%	C9399	Medical Drug Managment	Neuromusclar Drugs	Y	
Intra-Articular Hyaluronan Injections	Sodium hyaluronate 1%	J3490	Medical Drug Managment	Neuromusclar Drugs	Y	
Intra-Articular Hyaluronan Injections	Synjoynt	J7331	Medical Drug Managment	Neuromusclar Drugs	Y	
Intra-Articular Hyaluronan Injections	Synvisc, Synvisc-One	J7325	Medical Drug Managment	Neuromusclar Drugs	Y	
Intra-Articular Hyaluronan Injections	Triluron	J7332	Medical Drug Managment	Neuromusclar Drugs	Y	
Intra-Articular Hyaluronan Injections	TriVisc	J7329	Medical Drug Managment	Neuromusclar Drugs	Y	
Lanreotide	Somatuline	J1930	Medical Drug Managment	Endocrine and Metabolic Drugs	Y	
Lanreotide (Cipla)		J1932	Medical Drug Managment	Endocrine and Metabolic Drugs	Y	
Laronidase	Aldurazyme	J1931	Medical Drug Managment	Endocrine and Metabolic Drugs	Y	

Effective Date: 04/01/2024

Description	Alt Descriptions	HCPCs code	Program	Therapeutic Drug Category	HCSC (BCBS IL, MT, NM, OK, TX)	Drug Comments
Lecanemab-irmb	Leqembi	J0174	Medical Drug Managment	Psychotherapeutic and Neurological Agents - Miscellaneous	Y	
Lenacapavir Injenction	Sunlenca Injection	J1961	Medical Drug Managment	Anti-Infective Agents	Y	
Leuprolide acetate	Fensolvi	J1951	Medical Drug Managment	Endocrine and Metabolic Drugs	Y	
Leuprolide acetate	Lupron	J1950	Medical Drug Managment	Endocrine and Metabolic Drugs	Y	
Lumasiran	Oxlumo	J0224	Medical Drug Managment	Genitourinary Products	Y	
Luspatercept-aamt	Reblozyl	J0896	Medical Drug Managment	Hematological Agents	Y	
Mepolizumab	Nucala	J2182	Medical Drug Managment	Respiratory Agents	Y	
Methoxy Polyethylene Glycol-Epoetin Beta	Mircera, Mircera for NON-ESRD	J0888	Medical Drug Managment	Hematological Agents	Y	
Mirikizumab-mrkz, inj	OmvoH	C9399	Medical Drug Managment	Treatment of Ulcerative Colitis	Y	C9168 will replace C9399 for Omvoh, effective: 04/01/24
Mirikizumab-mrkz, inj	OmvoH	C9168	Medical Drug Managment	Treatment of Ulcerative Colitis	Y	C9168 will replace C9399 for Omvoh, effective: 04/01/24
Mirikizumab-mrkz, inj	OmvoH	J3590	Medical Drug Managment	Treatment of Ulcerative Colitis	Y	
Natalizumab	Tysabri	J2323	Medical Drug Managment	Psychotherapeutic and Neurological Agents - Miscellaneous	Y	
Nusinersen	Spinraza	J2326	Medical Drug Managment	Neuromusclar Drugs	Y	
Ocrelizumab	Ocrevus	J2350	Medical Drug Managment	Psychotherapeutic and Neurological Agents - Miscellaneous	Y	
Octreotide	Sandostatin	J2354	Medical Drug Managment	Endocrine and Metabolic Drugs	Y	
Octreotide	Sandostatin LAR	J2353	Medical Drug Managment	Endocrine and Metabolic Drugs	Y	
Olipudase alfa-rpcp	Xenpozyme	J0218	Medical Drug Managment	Endocrine and Metabolic Drugs	Y	
Omalizumab	Xolair	J2357	Medical Drug Managment	Respiratory Agents	Y	
OnabotulinumtoxinA	Botox	J0585	Medical Drug Managment	Neuromusclar Drugs	Y	
Onasemnogen abeparvovec-xioi	Zolgensma	J3399	Medical Drug Managment	Neuromusclar Drugs	Y	
Palivizumab	Synagis	90378	Medical Drug Managment	Biologicals	Y	
Pasireotide	Signifor LAR	J2502	Medical Drug Managment	Endocrine and Metabolic Drugs	Y	

Effective Date: 04/01/2024

Description	Alt Descriptions	HCPCs code	Program	Therapeutic Drug Category	HCSC (BCBS IL, MT, NM, OK, TX)	Drug Comments
Patisiran	Onpattro	J0222	Medical Drug Managment	Psychotherapeutic and Neurological Agents - Miscellaneous	Y	
Pegcetaplan	Syfovre	J2781	Medical Drug Managment	Dermatological/Anorectal /Mouth-Throat/Dental/Ophthalmic/Otic	Y	
Pegloticase	Krystexxa	J2507	Medical Drug Managment	Analgesics and Anesthetics	Y	
Pegunigalsidase alfa-iwxj	Elfabrio	J2508	Medical Drug Managment	Endocrine and Metabolic Drugs	Y	
Plasminogen, human-tvmh	Ryplazim	J2998	Medical Drug Managment	Hematological Agents	Y	
Pozelimab-bbfg	Veopoz	J9376	Medical Drug Managment	Treatment of CD55-deficient protein-losing enteropathy, also known as CHAPLE disease	Y	New Permanent HCPC Code: J9376 will replace NOC Code: C9399 & J3590 for Veopoz, effective: 04/01/24
Pozelimab-bbfg	Veopoz	C9399	Medical Drug Managment	Treatment of CD55-deficient protein-losing enteropathy, also known as CHAPLE disease	Y	New Permanent HCPC Code: J9376 will replace NOC Code: C9399 & J3590 for Veopoz, effective: 04/01/24
Pozelimab-bbfg	Veopoz	J3590	Medical Drug Managment	Treatment of CD55-deficient protein-losing enteropathy, also known as CHAPLE disease	Y	New Permanent HCPC Code: J9376 will replace NOC Code: C9399 & J3590 for Veopoz, effective: 04/01/24
Ranibizumab	Lucentis	J2778	Medical Drug Managment	Dermatological/Anorectal /Mouth-Throat/Dental/Ophthalmic/Otic	Y	
Ranibizumab	Susvimo	J2779	Medical Drug Managment	Dermatological/Anorectal /Mouth-Throat/Dental/Ophthalmic/Otic	Y	
Ranibizumab-eqrn	Cimerli	Q5128	Medical Drug Managment	Dermatological/Anorectal /Mouth-Throat/Dental/Ophthalmic/Otic	Y	
Ranibizumab-nuna	Byooviz	Q5124	Medical Drug Managment	Dermatological/Anorectal /Mouth-Throat/Dental/Ophthalmic/Otic	Y	
Ravulizumab-cwvz	Ultomiris	J1303	Medical Drug Managment	Hematological Agents	Y	
Remdesivir	Veklury	J0248	Medical Drug Managment	Anti-Infective Agents	Y	

Effective Date: 04/01/2024

Description	Alt Descriptions	HCPCs code	Program	Therapeutic Drug Category	HCSC (BCBS IL, MT, NM, OK, TX)	Drug Comments
Repository Corticotopin Injection	Cortrophin Gel	J3490	Medical Drug Managment	Endocrine and Metabolic Drugs	Y	
Reslizumab	Cinqair	J2786	Medical Drug Managment	Respiratory Agents	Y	
Rilonacept	Arcalyst	J2793	Medical Drug Managment	Analgesics and Anesthetics	Y	
RimabotulinumtoxinB	Myobloc	J0587	Medical Drug Managment	Neuromusclar Drugs	Y	
Risankizumab-rzaa	Skyrizi	J2327	Medical Drug Managment	Gastrointestinal Agents	Y	
Rituximab	Rituxan	J9312	Medical Drug Managment	Antineoplastic Agents and Adjunctive Therapies	Y	
Rituximab-abbs (Truxima)	Truxima	Q5115	Medical Drug Managment	Antineoplastic Agents and Adjunctive Therapies	Y	
Rituximab-arrx	Riabni	Q5123	Medical Drug Managment	Antineoplastic Agents and Adjunctive Therapies	Y	
Rituximab-pvvr	Ruxience	Q5119	Medical Drug Managment	Antineoplastic Agents and Adjunctive Therapies	Y	
Romiplostim	Nplate	J2796	Medical Drug Managment	Hematological Agents	Y	
Rozanolizumab-noli	Rystiggo	J9333	Medical Drug Managment	Miscellaneous Products	Y	
Sebelipase alfa	Kanuma	J2840	Medical Drug Managment	Endocrine and Metabolic Drugs	Y	
Secukinumab, inj	Cosentyx	C9399	Medical Drug Managment	Treatment of Psoriatic Arthritis, Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis.	Y	C9166 will replace C9399 for Cosentyx IV effective: 04/01/24
Secukinumab, inj	Cosentyx	C9166	Medical Drug Managment	Treatment of Psoriatic Arthritis, Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis.	Y	C9166 will replace C9399 for Cosentyx IV effective: 04/01/24
Secukinumab, inj	Cosentyx	J3590	Medical Drug Managment	Treatment of Psoriatic Arthritis, Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis.	Y	
Spesolimab-sbzo	Spevigo	J1747	Medical Drug Managment	Topical Products	Y	
Sutimlimab-jome	Enjaymo	J1302	Medical Drug Managment	Hematological Agents	Y	
Taliglucerase Alfa	Elelyso	J3060	Medical Drug Managment	Endocrine and Metabolic Drugs	Y	

Effective Date: 04/01/2024

Description	Alt Descriptions	HCPCs code	Program	Therapeutic Drug Category	HCSC (BCBS IL, MT, NM, OK, TX)	Drug Comments
Teplizumab-mzww	Tziold	J9381	Medical Drug Managment	Endocrine and Metabolic Drugs	Y	
Teprotumumab-trbw	Tepezza	J3241	Medical Drug Managment	Endocrine and Metabolic Drugs	Y	
Tezepelumab-ekko	Tezspire	J2356	Medical Drug Managment	Respiratory Agents	Y	
Tildrakizumab-asmn	Ilumya	J3245	Medical Drug Managment	Topical Products	Y	
Tocilizumab	Actemra	J3262	Medical Drug Managment	Analgesics and Anesthetics	Y	
Tocilizumab-bavi	Tofidence	C9399	Medical Drug Management	For the Treatment of: 1) Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs) 2) Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis. 3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.	Y	
Tocilizumab-bavi	Tofidence	J3490	Medical Drug Management	For the Treatment of: 1) Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs) 2) Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis. 3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.	Y	

Effective Date: 04/01/2024

Description	Alt Descriptions	HCPCs code	Program	Therapeutic Drug Category	HCSC (BCBS IL, MT, NM, OK, TX)	Drug Comments
Tocilizumab-bavi	Tofidence	J3590	Medical Drug Managment	For the Treatment of: 1) Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs) 2) Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis. 3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.	Y	
Tocilizumab-bavi	Tofidence	J9999	Medical Drug Managment	For the Treatment of: 1) Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs) 2) Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis. 3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.	Y	
Tofersen	Qalsody	J1304	Medical Drug Managment	Neuromusclar Drugs	Y	
Treprostinil	Remodulin	J3285	Medical Drug Managment	Cardiovascular Agents	Y	
Triamcinolone ER	Zilretta	J3304	Medical Drug Managment	Endocrine and Metabolic Agents	Y	
Triptorelin ER	Triptodur	J3316	Medical Drug Managment	Endocrine and Metabolic Drugs	Y	

Effective Date: 04/01/2024

Description	Alt Descriptions	HCPCs code	Program	Therapeutic Drug Category	HCSC (BCBS IL, MT, NM, OK, TX)	Drug Comments
Ublituximab-xiiy	Briumvi	J2329	Medical Drug Managment	Psychotherapeutic and Neurological Agents - Miscellaneous	Y	
Ustekinumab	Stelara	J3358	Medical Drug Managment	Topical Products	Y	
Ustekinumab	Stelara	J3357	Medical Drug Managment	Topical Products	Y	
Valoctocogene Roxaparvovec-rvox	Roctavian	J1412	Medical Drug Managment	Hematological Agents	Y	
Valoctocogene Roxaparvovec-rvox	Roctavian	C9399	Medical Drug Managment	Hematological Agents	Y	
Valoctocogene Roxaparvovec-rvox	Roctavian	J3590	Medical Drug Managment	Hematological Agents	Y	
Vedolizumab	Entyvio	J3380	Medical Drug Managment	Gastrointestinal Agents	Y	
Velaglucerase Alfa	Vpriv	J3385	Medical Drug Managment	Hematological Agents	Y	
Velmanase alfa-tycv	Lamzede	J0217	Medical Drug Managment	Endocrine and Metabolic Drugs	Y	
Vestronidase alfa-vjbk	Mepsevii	J3397	Medical Drug Managment	Endocrine and Metabolic Drugs	Y	
Viltolarsen	Viltepso	J1427	Medical Drug Managment	Neuromusclar Drugs	Y	
Voretigene Neparvovec-rzyl	Luxturna	J3398	Medical Drug Managment	Dermatological/Anorectal /Mouth-Throat/Dental/Ophthalmic/Otic	Y	
Vutrusiran	Amvuttra	J0225	Medical Drug Managment	Psychotherapeutic and Neurological Agents - Miscellaneous	Y	
Zoledronic Acid	Reclast	J3489	Medical Drug Managment	Endocrine and Metabolic Drugs	Y	